Solvonis Therapeutics PLC
SVNS · Main Market · Health Care · mcap £8.7m · 0.1p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 06 Oct 26 | Investor Webinar – 15 October 2026
Building a leader in addiction and mental health therapeutics |
+3.0% | |
| 30 Sep 26 | Notification of Admission of Shares and TVR
LONDON - 30 September 2026 - Solvonis Therapeutics plc (LSE: SVNS), a late clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, a |
+0.0% | |
| 30 Sep 26 | Results | Unaudited interim results
Unaudited interim results for the six months to 30 June 2026 |
+0.0% |
| 29 Sep 26 | New Analysis Identifies Major AUD Breakthrough
New Analysis Identifies Major AUD Breakthrough: SVN-001 Ahead of Established and Emerging AUD Treatments in Cross-Trial Analysis |
+0.0% | |
| 03 Sep 26 | Vital Patent milestone achieved– SVN 114
Composition-of-matter allowance strengthens proprietary position in a large and increasingly strategic PTSD market |
+1.7% | |
| 25 Aug 26 | Solvonis Raises £1.3 Million
Solvonis Raises £1.3 Million to Advance Key Clinical and Regulatory Milestones |
−12.9% | |
| 11 Aug 26 | Solvonis to Present at WTR Conference
Solvonis to Present at WTR Virtual Insights Conference |
+0.0% | |
| 06 Aug 26 | SVN-015 Advances into Further NIDA-Funded Studies
SVN-015 Advances into Further NIDA-Funded Studies Following Encouraging Initial Screening |
+3.6% | |
| 13 Jul 26 | Research Coverage Initiation
Water Tower Research Initiates Coverage, Highlighting Significant AUD Market and Valuation Opportunity |
+7.4% | |
| 22 Jun 26 | Announces Positive Bridging Data Supporting
PK Data Support Scientific Bridge to Approved Intranasal Esketamine Reference Product |
+11.1% | |
| 19 Jun 26 | Result of AGM
LONDON - June 19, 2026 - Solvonis Therapeutics plc (LSE: SVNS) ("Solvonis" or the "Company"), a late clinical stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous s |
−0.5% | |
| 27 May 26 | Routine | Notice of AGM | |
| 05 May 26 | CSO Speaks at National Research Meeting
Solvonis Chief Scientific Officer Professor David Nutt to Speak at U.S. |
−6.0% | |
| 29 Apr 26 | Results | Final Results
FY2025 transformation complete as Board refines strategy around the SVN-001 Phase 3 value inflection point |
−10.8% |
| 22 Apr 26 | Appointment of Water Tower Research
Appoints Water Tower Research to deepen U.S. market understanding, refine Company profile and expand institutional investor reach |
−1.6% | |
| 20 Apr 26 | US CNS Executive Order
Welcomes President Trump's Executive Order as a positive signal for rapid-acting CNS therapies in the United States |
+9.3% | |
| 08 Apr 26 | Granted U.S. Patent from PTSD Discovery Programme
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces that it has been granted a sec |
+0.0% | |
| 31 Mar 26 | Granted U.S. Patent from PTSD Discovery Programme
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces it has been granted a U.S. pat |
−2.0% | |
| 10 Mar 26 | SVN-114 selected for PTSD discovery programme
SVN-114 selected as the lead candidate for PTSD discovery programme |
+0.4% | |
| 28 Jan 26 | Expansion of SVN-015 into depression
Expansion of SVN-015 into depression following positive preclinical data |
−5.6% | |
| 07 Jan 26 | US Patent allowance for PTSD discovery programme
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces that it has received a Notice of Allowance (the |
+3.2% | |
| 22 Dec 25 | Research and Development Update – Q4 2025
Pipeline advancing across addiction and psychiatry with multiple 2026 catalysts |
−10.7% | |
| 03 Dec 25 | SVN-015 accepted into US NIDA funded programme
Solvonis' Novel Compound SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction |
+2.5% | |
| 31 Oct 25 | Routine | Total Voting Rights | |
| 31 Oct 25 | Corporate Structure Update and Issue of Options
Corporate Structure Update, Disposal of Non-Core Subsidiary, and Issue of Options |
−3.1% | |
| 27 Oct 25 | Appoints global biopharma leader Paul Carter
Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth |
+0.0% | |
| 16 Oct 25 | Raises £1.25 Million to Accelerate Programmes
Raises £1.25 Million to Accelerate Programmes in High-Burden CNS Disorders |
−2.6% |
Company filings. Not investment advice.